Samidorphan

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Samidorphan
ALKS-33.png
Clinical data
Legal status
?
Identifiers
CAS number 852626-89-2 YesY
ATC code ?
PubChem CID 11667832
ChemSpider 23259667
UNII 7W2581Z5L8 YesY
KEGG D10162 YesY
Chemical data
Formula C21H26N2O4 
Mol. mass 370.441 g/mol

Samidorphan (ALKS-33) is a selective opioid antagonist which blocks the μ-opioid receptor, but without affecting the δ-opioid or κ-opioid receptors. It has been investigated for the treatment of alcoholism and cocaine addiction,[1][2] showing similar efficacy to naltrexone but possibly with reduced side effects. However it has attracted much more attention as part of the combination product ALKS 5461, where samidorphan is combined with the mixed μ-opioid agonist and κ-opioid antagonist opioid modulator buprenorphine, as an antidepressant. Buprenorphine has shown antidepressant effects in some human studies, thought to be because of its antagonist effects at the κ-opioid receptor, but has not been further developed for this application because of its μ-opioid agonist effects and consequent abuse potential. By combining buprenorphine with samidorphan to block the μ-opioid agonist effects, the combination acts more like a selective κ-opioid antagonist, and produces only antidepressant effects, without typical μ-opioid effects being evident.[3][4]

See also[edit]

References[edit]

  1. ^ Hillemacher, T.; Heberlein, A.; Muschler, M. A.; Bleich, S.; Frieling, H. (2011). "Opioid modulators for alcohol dependence". Expert Opinion on Investigational Drugs 20 (8): 1073–1086. doi:10.1517/13543784.2011.592139. PMID 21651459.  edit
  2. ^ ALK33BUP-101: Safety and Pharmacodynamic Effects of ALKS 33-BUP Administered Alone and When Co-administered With Cocaine
  3. ^ ALKS 5461 drug found to reduce depressive symptoms in Phase 1/2 study
  4. ^ Investigational ALKS 5461 Channels ‘Opium Cure’ for Depression